Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 2, 2010, Pages 115-131

  Kumar, Santosh ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Biocatalyst; Cytochrome P450; Directed evolution; Drug metabolism; Drug toxicity; Protein engineering

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; AMODIAQUINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DRUG METABOLITE; ERYTHROMYCIN; FLURBIPROFEN; LIMONENE; PACLITAXEL; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TETRACENOMYCIN C; WARFARIN;

ANTINEOPLASTIC ACTIVITY; BIOCATALYST; BIOREMEDIATION; BIOSENSOR; BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG MONITORING; DRUG POTENCY; DRUG SYNTHESIS; ELECTRODE; ENZYME ENGINEERING; ENZYME STABILITY; FERMENTATION; FREEZE DRYING; GENE DIRECTED ENZYME PRODRUG THERAPY; HETEROLOGOUS EXPRESSION; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BIOCATALYSIS; BIODEGRADATION, ENVIRONMENTAL; BIOMEDICAL ENGINEERING; BIOSENSING TECHNIQUES; BIOTECHNOLOGY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; ENZYMES, IMMOBILIZED; GENE THERAPY; HUMANS; PROTEIN ENGINEERING;

MAMMALIA;

EID: 76749092561     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903431040     Document Type: Review

References (156)

1. Isin EM, Guengerich FP. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta 2007;1770:314-329
2. Anzenbacher P, Anzenbacherova F. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-747
3. Available from: http://drnelson.utmem. edu/CytochromeP450.html
4. Coon MJ. Cytochrome P450: nature's most versatile biological catalyst. Ann Rev Pharmacol Toxicol 2005;45:1-25
5. Murataliev MB, Klein M, Fulco A, Feyereisen R. Functional interactions in cytochrome P450BM3: flavin semiquinone intermediates, role of NADP (H), and mechanism of electron transfer by the flavoprotein domain. Biochemistry 1997;36:8401-8412
6. Sligar SG. Coupling of spin, substrate, and redox equilibria in cytochrome P450. Biochemistry 1976;615:5399-5406
7. Braeuning A. Regulation of cytochrome P450 expression by Ras- and beta-catenin-dependent signaling. Curr Drug Metab 2009;10:138-158
8. Davydov DR, Halpert JR. Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol 2008;4:1523-1535
9. Tracy TS. Atypical cytochrome P450 kinetics: implications for drug discovery. Drugs RD 2006;7:349-363
10. Boobis A, Watelet JB, Whomsley R, et al. Drug interactions. Drug Metab Rev 2009;41:486-552
11. Zhao YH, Halpert JR. Structure-function analysis of cytochromes P450 2B. Arch Biochem Biophys 2007;1770:402-412
12. Guengerich FP. Cytochrome P450 enzymes in the generation of commercial products. Nat Rev Drug Discov 2002;1:359-366
13. Guengerich FP. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch Biochem Biophys 2003;409:59-71
14. Urlacher VB, Lutz-Wahl S, Schmid RD. Microbial P450 enzymes in biotechnology. Appl Microbiol Biotechnol 2004;64:317-325
15. Gillam EM. Exploring the potential of xenobiotic-metabolising enzymes as biocatalysts: evolving designer catalysts from polyfunctional cytochrome P450 enzymes. Clin Exp Pharmacol Physiol 2005;32:147-152
16. Bernhardt R. Cytochromes P450 as versatile biocatalysts. J Biotechnol 2006;124:128-145
17. McLean KJ, Girvan HM, Munro AW. Cytochrome P450/redox partner fusion enzymes: biotechnological and toxicological prospects. Expert Opin Drug Metab Toxicol 2007;3:847-863
18. Julsing MK, Cornelissen S, Bühler B, Schmid A. Heme-iron oxygenases: powerful industrial biocatalysts? Curr Opin Chem Biol 2008;12:177-186
19. Morant M, Bak S, Møller BL, Werck-Reichhart D. Plant cytochromes P450: tools for pharmacology, plant protection and phytoremediation. Curr Opin Biotechnol 2003;14:151-162
20. Gillam EM. Engineering cytochrome P450 enzymes. Chem Res Toxicol 2008;21:220-231
21. Abhilash PC, Jamil S, Singh N. Transgenic plants for enhanced biodegradation and phytoremediation of organic xenobiotics. Biotechnol Adv 2009;27:474-488
22. Chen L, Waxman DJ. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002;8:1405-1416
23. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-359
24. Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 2006;20:176-186
25. Sonomoto K, Hoq MM, Tanaka A, Fukui S. 11beta-Hydroxylation of cortexolone (reichstein compound S) to hydrocortisone by curvularia lunata entrapped in photo-cross-linked resin gels. Appl Environ Microbiol 1983;45:436-443
26. Available from: http://www.schering.de
27. Fujii T, Fujii Y, Machida K, et al. Efficient biotransformations using Escherichia coli with tolC acrAB mutations expressing cytochrome P450 genes. Biosci Biotechnol Biochem 2009;73:805-810
28. Falck JR, Reddya YK, Hainesa DC, et al. Practical enantiospecific syntheses of 14,15-EET and leukotoxin B (vernolic acid). Tetrahedron Lett 2001;42:4131-4133
29. Shafiee A, Hutchinson CR. Macrolide antibiotic biosynthesis: isolation and properties of two forms of 6-deoxyerythronolide B hydroxylase from saccharopolyspora erythraea (streptomyces erythreus). Biochemistry 1987;26:6204-6210
30. Jennewein S, Rithner CD, Williams RM, Croteau RB. Taxol biosynthesis: taxane 13 alpha-hydroxylase is a cytochrome P450-dependent monooxygenase. Proc Natl Acad Sci USA 2001;98:13595-13600
31. van Beilen JB, Holtackers R, Luscher D, et al. Biocatalytic production of perillyl alcohol from limonene by using a novel Mycobacterium sp. cytochrome P450 alkane hydroxylase expressed in pseudomonas putida. Appl Environ Microbiol 2005;71:1737-1744
32. Vail RB, Homann MJ, Hanna I, Zaks A. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9, and 1A2 with NADPH-P450 reductase expressed in escherichia coli. J Ind Microbiol Biotechnol 2005;32:67-74
33. Ueda Y, Morigaki K, Tatsu Y, et al. Immobilization and activity assay of cytochrome P450 on patterned lipid membranes. Biochem Biophys Res Commun 2007;355:926-931
34. Nicoli R, Bartolini M, Rudaz S, et al. Development of immobilized enzyme reactors based on human recombinant cytochrome P450 enzymes for phase I drug metabolism studies. J Chromatogr A 2008;1206:2-10
35. Gannett PM, Kabulski J, Perez FA, et al. Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9. J Am Chem Soc 2006;128:8374-8375
36. Mie Y, Suzuki M, Komatsu Y. Electrochemically driven drug metabolism by membranes containing human cytochrome P450. J Am Chem Soc 2009;131:6646-6647
37. Royo JL, Moreno-Ruiz E, Cebolla A, Santero E. Stable long-term indigo production by overexpression of dioxygenase genes using a chromosomal integrated cascade expression circuit. J Biotechnol 2005;116:113-124
38. Gillam EM, Aguinaldo AM, Notley LM, et al. Formation of indigo by recombinant mammalian cytochrome P450. Biochem Biophys Res Commun 1999;265:469-472
39. Warzecha H, Frank A, Peer M, et al. Formation of the indigo precursor indican in genetically engineered tobacco plants and cell cultures. Plant Biotechnol J 2007;5:185-191
40. Gillam EM, Guengerich FP. Exploiting the versatility of human cytochrome P450 enzymes: the promise of blue roses from biotechnology. IUBMB Life 2001;52:271-277
41. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-972
42. Huang Z, Raychowdhury MK, Waxman DJ. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther 2000;7:1034-1042
43. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998;58:4391-4401
44. Jounaidi Y, Waxman DJ. Use of replication-condition adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes in cancer therapy. Cancer Res 2004;64:292-303
45. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004;65:1278-1285
46. Chen CS, Jounaidi Y, Waxman DJ. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos 2005;33:1261-1267
47. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997;7:211-221
48. Jounaidi Y, Waxman DJ. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P450 reductase-based cancer gene therapy. Cancer Res 2001;61:4437-4444
49. Hunt S. Technology evaluation: MetXia-P450. Oxford Biomedica. Curr Opin Mol Ther 2001;3:595-598
50. Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther 2006;5:541-555
51. Ma Y, Waxman DJ. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther 2007;6:2879-2890
52. Chen CS, Jounaidi Y, Su T, Waxman DJ. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther 2007;14:935-944
53. Bistolas N, Wollenberger U, Jung C, Scheller FW. Cytochrome P450 biosensors-a review. Biosens Bioelectron 2005;20:2408-2423
54. Bozina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009;60:217-242
55. Alonso-Lomillo MA, Yardimci C, Domínguez-Renedo O, Arcos-Martínez MJ. CYP450 2B4 covalently attached to carbon and gold screen printed electrodes by diazonium salt and thiols monolayers. Anal Chim Acta 2009;633:51-56
56. Ignaszak A, Hendricks N, Waryo T, et al. Novel therapeutic biosensor for indinavir-a protease inhibitor antiretroviral drug. J Pharm Biomed Anal 2009;49:498-501
57. Ferrero VE, Andolfi L, Di Nardo G, et al. Protein and electrode engineering for the covalent immobilization of P450 BMP on gold. Anal Chem 2008;80:8438-8446
58. Carrara S, Shumyantseva VV, Archakov AI, Samorì B. Screen-printed electrodes based on carbon nanotubes and cytochrome P450scc for highly sensitive cholesterol biosensors. Biosens Bioelectron 2008;24:148-150
59. Alonso-Lomillo MA, Gonzalo-Ruiz J, Domínguez-Renedo O, et al. CYP450 biosensors based on gold chips for antiepileptic drugs determination. Biosens Bioelectron 2008;23:1733-1737
60. Liu S, Peng L, Yang X, et al. Electrochemistry of cytochrome P450 enzyme on nanoparticle-containing membrane-coated electrode and its applications for drug sensing. Anal Biochem 2008;375:209-216
61. Iwuoha E, Ngece R, Klink M, Baker P. Amperometric responses of CYP2D6 drug metabolism nanobiosensor for sertraline: a selective serotonin reuptake inhibitor. IET Nanobiotechnol 2007;1:62-67
62. Shumyantseva VV, Bulko TV, Archakov AI. Electrochemical reduction of cytochrome P450 as an approach to the construction of biosensors and bioreactors. J Inorg Biochem 2005;99:1051-1063
63. Paternolli C, Antonini M, Ghisellini P, Nicolini C. Recombinant cytochrome p450 immobilization for biosensor applications. Langmuir 2004;20:11706-11712
64. Fantuzzi A, Meharenna YT, Briscoe PB, et al. Improving catalytic properties of P450BM3 haem domain electrodes by molecular Lego. Chem Commun (Camb) 2006;28:1289-1291
65. Vehlow J, Bergfeldt B, Hunsinger H. PCDD/F and related compounds in solid residues from municipal solid waste incineration-a literature review. Waste Manag Res 2006;24:404-420
66. Ishaq R, Naf C, Zebühr Y, et al. PCBs, PCNs, PCDD/Fs, PAHs and Cl-PAHs in air and water particulate samples-patterns and variations. Chemosphere 2003;50:1131-1150
67. Sakaki T, Shinkyo R, Takita T, et al. Biodegradation of polychlorinated dibenzo-p-dioxins by recombinant yeast expressing rat CYP1A subfamily. Arch Biochem Biophys 2002;401:91-98
68. Shinkyo R, Sakaki T, Takita T, et al. Generation of 2,3,7,8-TCDD- metabolizing enzyme by modifying rat CYP1A1 through site-directed mutagenesis. Biochem Biophys Res Commun 2003;308:511-517
69. Shinkyo R, Kamakura M, Ikushiro S, et al. Biodegradation of dioxins by recombinant Escherichia coli expressing rat CYP1A1 or its mutant. Appl Microbiol Biotechnol 2006;72:584-590
70. Preston BD, Allen JR. 2,2¢,5,5¢-Tetrachlorobiphenyl: isolation and identification of metabolites generated by rat liver microsomes. Drug Metab Dispos 1998;08:197-203
71. Waller SC, He YA, Harlow GR, et al. 2,2¢,3,3¢,6,6¢- hexachlorobiphenyl hydroxylation by active site mutants of cytochrome P450 2B1 and 2B11. Chem Res Toxicol 1999;12:690-699
72. Billet S, Abbas I, Le Goff J, et al. Genotoxic potential of polycyclic aromatic hydrocarbons-coated onto airborne Particulate Matter (PM 2.5) in human lung epithelial A549 cells. Cancer Lett 2008;270:144-155
73. Morant M, Bak S, Møller BL, Werck-Reichhart D. Plant cytochromes P450: tools for pharmacology, plant protection and phytoremediation. Curr Opin Biotechnol 2003;14:151-162
74. Van Aken B. Transgenic plants for enhanced phytoremediation of toxic explosives. Curr Opin Biotechnol 2009;20:231-236
75. Abhilash PC, Jamil S, Singh N. Transgenic plants for enhanced biodegradation and phytoremediation of organic xenobiotics. Biotechnol Adv 2009;27:474-488
76. Kawahigashi H. Transgenic plants for phytoremediation of herbicides. Curr Opin Biotechnol 2009;20:225-230
77. Inui H, Ohkawa H. Herbicide resistance in transgenic plants with mammalian P450 monooxygenase genes. Pest Manag Sci 2005;61:286-291
78. Rylott EL, Jackson RG, Edwards J, et al. An explosive-degrading cytochrome P450 activity and its targeted application for the phytoremediation of RDX. Nat Biotechnol 2006;24:216-219
79. Kawahigashi H, Hirose S, Ohkawa H, Ohkawa Y. Phytoremediation of the herbicides atrazine and metolachlor by transgenic rice plants expressing human CYP1A1, CYP2B6, and CYP2C19. J Agric Food Chem 2006;54:2985-2991
80. Kawahigashia H, Hirosea S, Ohkawab H, Ohkawa Y. Herbicide resistance of transgenic rice plants expressing human CYP1A1. Biotechnol Adv 2007;25:75-84
81. Kawahigashi H, Hirose S, Ohkawa H, Ohkawa Y. Transgenic rice plants expressing human P450 genes involved in xenobiotic metabolism for phytoremediation. J Mol Microbiol Biotechnol 2008;15:212-219
82. James CA, Xin G, Doty SL, Strand SC. Degradation of low molecular weight volatile organic compounds by plants genetically modified with mammalian cytochrome P450 2E1. Environ Sci Technol 2008;42:289-293
83. Munro AW, Girvan HM, McLean KJ. Cytochrome P450-redox partner fusion enzymes. Biochim Biophys Acta 2007;1770:345-359
84. Cheng J, Wan DF, Gu JR, et al. Establishment of a yeast system that stably expresses human cytochrome P450 reductase: application for the study of drug metabolism of cytochrome P450s in vitro. Protein Expr Purif 2006;47:467-476
85. Peters FT, Dragan CA, Kauffels A, et al. Biotechnological synthesis of the designer drug metabolite 4¢-hydroxymethyl-alphapyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-a versatile alternative to multistep chemical synthesis. J Anal Toxicol 2009;33:190-197
86. Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008;259:1-15
87. Parikh A, Gillam EM, Guengerich FP. Drug metabolism by escherichia coli expressing human cytochromes P450. Nat Biotechnol 1997;15:784-788
88. Kumar S, Halpert JR. Use of directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts. Biochem Biophys Res Commun 2006;338:456-464
89. Otey CR, Landwehr M, Endelman JB, et al. Structure-guided recombination creates an artificial family of cytochromes P450. PLoS Biol 2006;4:e112
90. Rosic NN, Huang W, Johnston WA, et al. Extending the diversity of cytochrome P450 enzymes by DNA family shuffling. Gene 2007;395:40-48
91. Ivanciuc O, Oezguen N, Mathura VS, et al. Using property based sequence motifs and 3D modeling to determine structure and functional regions of proteins. Curr Med Chem 2004;11:583-593
92. Ivanciuc O, Braun W. Robust quantitative modeling of peptide binding affinities for MHC molecules using physical-chemical descriptors. Protein Pept Lett 2007;14:903-916
93. Negi SS, Braun W. Statistical analysis of physical-chemical properties and prediction of protein-protein interfaces. J Mol Model 2007;13:1157-1167
94. Oezguen N, Kumar S, Hindupur A, et al. Identification and analysis of conserved motifs in cytochrome P450 family 2: functional role of a motif 187RFDYKD192 in P450 2B enzymes. J Biol Chem 2008;283:21808-21816
95. Yuen CM, Liu DR. Dissecting protein structure and function using directed evolution. Nat Methods 2007;4:995-997
96. Woycechowsky KJ, Vamvaca K, Hilvert D. Novel enzymes through design and evolution. Adv Enzymol Relat Areas Mol Biol 2007;75:241-294
97. Joo H, Lin Z, Arnold FH. Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation. Nature 1999;399:670-672
98. Schwaneberg U, Otey C, Cirino PC, et al. Cost-effective whole-cell assay for laboratory evolution of hydroxylases in escherichia coli. J Biomol Screen 2001;6:111-117
99. Kumar S, Chen CS, Waxman DJ, Halpert JR. Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem 2005;280:9569-9575
100. Kumar S, Liu H, Halpert JR. Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substarte oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos 2006;34:1958-1965
101. Kim D, Guengerich FP. Enhancement of 7-methoxyresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding. Arch Biochem Biophys 2004;432:102-108
102. Kim D, Guengerich FP. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J Biol Chem 2005;280:40319-40327
103. Kumar S. Identification of a novel laser dye substrate of mammalian cytochromes P450: application in rapid kinetic analysis, inhibitor screening, and directed evolution. J Biolmol Screen 2007;12:677-682
104. Salazar O, Cirino PC, Arnold FH. Thermostabilization of a cytochrome P450 peroxygenase. ChemBioChem 2003;4:891-893
105. Wong TS, Arnold FH, Schwaneberg U. Laboratory evolution of cytochrome P450BM3 monooxygenase for organic cosolvents. Biotechnol Bioeng 2004;85:351-358
106. Kumar S, Sun L, Liu H, et al. Engineering mammalian cytochrome P450 2B1 by directed evolution for enhanced catalytic tolerance to temperature and dimethyl sulfoxide. Protein Eng Des Sel 2006;19:547-554
107. Aucamp JP, Cosme AM, Lye GJ, Dalby PA. High-throughput measurement of protein stability in microtiter plates. Biotechnol Bioeng 2005;89:599-607
108. Bergquist PL, Hardiman EM, Ferrari BC, Winsley T. Applications of flow cytometry in environmental microbiology and biotechnology. Extremophiles 2009;13:389-401
109. Bershtein S, Tawfik DS. Advances in laboratory evolution in enzymes. Cur Opin Chem Biol 2008;12:151-158
110. Gupta RD, Tawfik DS. Directed enzyme evolution via small and effective neutral drift libraries. Nat Methods 2008;5:939-942
111. Farinas ET, Schwaneberg U, Glieder A, Arnond FH. Directed evolution of a cytochrome P450 mooxygenase for alkane oxidation. Adv Synth Catal 2001;343:601-606
112. Glieder A, Farinas ET, Arnold FH. Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase. Nat Biotechnol 2002;20:1135-1139
113. Cirino PC, Arnold FH. A self-sufficient peroxide-driven hydroxylation biocatalyst. Angew Chem Int Ed 2003;42:3299-3301
114. Peters MW, Meinhold P, Glieder A, Arnold FH. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450BM3. J Am Chem Soc 2003;125:13442-13450
115. Bloom JD, Labthavikul ST, Otey CR, Arnold FH. Protein stability promotes evolvability. Proc Natl Acad Sci USA 2006;103:5869-5874
116. Meinhold P, Peters MW, Chen MMY, et al. Direct conversion of ethane to ethanol by engineered cytochrome P450BM3. ChemBioChem 2005;6:1765-1768
117. Otey CR, Bandara G, Lalonde J, et al. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol Bioeng 2005;93:494-499
118. Landwehr M, Hochrein L, Otey CR, et al. Enantioselective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450BM3. J Am Chem Soc 2006;128:6058-6059
119. Kubo T, Peters MW, Meinhold P, Arnold FH. Enantioselective epoxidation of terminal alkenes to (R)- and (S)-epoxides by engineered cytochromes P450BM3. Chemistry 2006;12:1216-1220
120. Fasan R, Chen MM, Crook NC, Arnold FH. Engineered alkane-hydroxylating cytochrome P450BM3 exhibiting native-like catalytic properties. Angew Chem Int Ed Engl 2007;46:8414-8418
121. Li HM, Mei LH, Urlacher VB, Schmid RD. Cytochrome P450BM3 evolved by random and saturation mutagenesis as an effective indole-hydroxylating catalyst. Appl Biochem Biotechnol 2008;144:27-36
122. Damsten MC, van Vugt-Lussenburg BMA, Zeldenthuis T, et al. Application of drug metabolizing mutants of cytochrome P450BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 2008;171:96-107
123. Whitehouse CJ, Bell SG, Yang W, et al. A highly active single-mutation variant of P450BM3 (CYP102A1). Chembiochem 2009;10:1654-1656
124. Whitehouse CJ, Bell SG, Tufton HG, et al. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options. Chem Commun (Camb) 2008;28:966-968
125. Walsh ME, Kyritsis P, Eady NA, et al. Catalytic reductive dehalogenation of hexachloroethane by molecular variants of cytochrome P450CAM (CYP101). Eur J Biochem 2000;67:5815-5820
126. Bell SG, Stevenson JA, Boyd HD, et al. Butane and propane oxidation by engineered cytochrome P450CAM. Chem Commun (Camb) 2002;7:490-491
127. Jones JP, O'Hare EJ, Wong LL. Oxidation of polychlorinated benzenes by genetically engineered CYP101 (cytochrome P450CAM). Eur J Biochem 2001;268:1460-1467
128. Harford-Cross CF, Carmichael AB, Allan FK, et al. Protein engineering of cytochrome P450CAM (CYP101) for the oxidation of polycyclic aromatic hydrocarbons. Protein Eng 2000;13:121-128
129. Bell SG, Harford-Cross CF, Wong LL. Engineering the CYP101 system for in vivo oxidation of unnatural substrates. Protein Eng 2001;14:797-802
130. Xu F, Bell SG, Lednik J, et al. The heme monooxygenase cytochrome P450CAM can be engineered to oxidize ethane to ethanol. Angew Chem Int Ed Engl 2005;44:4029-4032
131. Nakamura K, Martin MV, Guengerich FP. Random mutagenesis of human cytochrome P450 2A6 and screening with indole oxidation products. Arch Biochem Biophys 2001;395:25-31
132. Yun CH, Miller MP, Guengerich FH. Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 2000;39:11319-11329
133. Kim D, Guengerich FP. Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation. Biochemistry 2004;43:981-988
134. Wu Z, Guengerich FP. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J Biol Chem 2005;280:41090-41100 (Pubitemid 41780604)
135. Zhang ZG, Liu Y, Guengerich FP, et al. Identification of amino acid residues involved in 4-chloroindole 3-hydroxylation by cytochrome P450 2A6 using screening of random libraries. J Biotechnol 2009;139:12-18
136. Scott EE, Spatzenegger M, Halpert JR. A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 2001;395:57-68
137. Cosme J, Johnson EF. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 2000;275:2545-2553
138. Williams PA, Cosme J, Sridhar V, et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000;5:121-131
139. Johnson EF, Stout CD. Structural diversity of human xenobiotic- metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 2005;338:331-336
140. Scott EE, Halpert JR. Structures of cytochrome P450 3A4. Trends Biochem Sci 2005;30:5-7
141. Kumar S, Zhao Y, Sun L, et al. Engineering human cytochrome P450 2B6 for enhanced expression and stability: importance of Leu264!Phe substitution. Mol Pharmacol 2007;72:1191-1199
142. Sun L, Chen CS, Waxman DJ, et al. Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Arch Biochem Biophys 2007;458:167-174
143. Domanski TL, Halpert JR. Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2001;2:117-137
144. Kumar S, Scott EE, Liu H, Halpert JR. A rational approach to re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5. J Biol Chem 2003;278:17178-17184
145. Scott EE, He YQ, Halpert JR. Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F-G region in P450 2B1. Chem Res Toxicol 2002;15:1407-1413
146. Hernandez CE, Kumar S, Liu H, Halpert JR. Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys 2006;455:61-67
147. Gillam EM. Extending the capabilities of nature's most versatile catalysts: directed evolution of mammalian xenobiotic-metabolizing P450s. Arch Biochem Biophys 2007;464:176-186
148. Huang W, Johnston WA, Hayes MA, et al. A shuffled CYP2C library with a high degree of structural integrity and functional versatility. Arch Biochem Biophys 2007;467:193-205 (Pubitemid 350050891)
149. Johnston WA, Huang W, De Voss JJ, et al. A shuffled CYP1A library shows both structural integrity and functional diversity. Drug Metab Dispos 2007;35:2177-2185 (Pubitemid 350146203)
150. Johnston WA, Huang W, De Voss JJ, et al. Quantitative whole-cell cytochrome P450 measurement suitable for high-throughput application. J Biomol Screen 2008;13:135-141
151. Keizers PH, Schraven LH, de Graaf C, et al. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem Biophys Res Commun 2005;338:1065-1074
152. Kumar S, Davydov DR, Halpert JR. Role of cytochrome b5 in modulating peroxide-supported CYP3A4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 2005;33:1131-1136
153. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
154. Baillie TA. Metabolism and toxicity of drugs: two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008;21:129-137
155. Hara M, Iazvovskaia S, Ohkawa H, et al. Immobilization of P450 monooxygenase and chloroplast for use in light-driven bioreactors. J Biosci Bioeng 1999;87:793-797
156. Dohr O, Paine MJI, Friedberg T, et al. Engineering of a functional human NADH-dependent cytochrome P450 system. Proc Natl Acad Sci USA 2001;98:81-86